Article
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Antimicrobial agents and chemotherapy - 1 Mar 2010
Moya Bartolome, Zamorano Laura, Juan Carlos, Pérez José L, Ge Yigong, Oliver Antonio
Abstract excerpt
CXA-101, previously designated FR264205, is a new antipseudomonal cephalosporin. We evaluated the activity of CXA-101 against a highly challenging collection of beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit (ICU)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.